Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Payables (2016 - 2025)

ProQR Therapeutics' Payables history spans 6 years, with the latest figure at $346885.0 for Q4 2025.

  • On a quarterly basis, Payables rose 1928.86% to $346885.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $346885.0, a 1928.86% increase, with the full-year FY2025 number at $346885.0, up 1928.86% from a year prior.
  • Payables hit $346885.0 in Q4 2025 for ProQR Therapeutics, up from $17097.5 in the prior quarter.
  • Over the last five years, Payables for PRQR hit a ceiling of $21.5 billion in Q1 2021 and a floor of $17097.5 in Q4 2024.
  • Historically, Payables has averaged $1.5 billion across 5 years, with a median of $414226.8 in 2022.
  • Biggest five-year swings in Payables: crashed 100.0% in 2022 and later soared 1928.86% in 2025.
  • Tracing PRQR's Payables over 5 years: stood at $5.7 million in 2021, then tumbled by 92.95% to $399937.0 in 2022, then soared by 314.57% to $1.7 million in 2023, then plummeted by 98.97% to $17097.5 in 2024, then soared by 1928.86% to $346885.0 in 2025.
  • Business Quant data shows Payables for PRQR at $346885.0 in Q4 2025, $17097.5 in Q4 2024, and $1.7 million in Q4 2023.